The stress response and the hypothalamic-pituitary-adrenal axis: from molecule to melancholia.
暂无分享,去创建一个
F. Shanahan | F Shanahan | T M O'Connor | D J O'Halloran | Terry O'Connor | D. O'halloran | T. O'Connor
[1] D. Boumpas,et al. Glucocorticoid Therapy for Immune-Mediated Diseases: Basic and Clinical Correlates , 1993, Annals of Internal Medicine.
[2] G. Chrousos,et al. Stress and reproduction: physiologic and pathophysiologic interactions between the stress and reproductive axes. , 1988, Advances in experimental medicine and biology.
[3] J. Cidlowski,et al. Regulation of apoptosis by steroid hormones , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[4] R. Schleimer,et al. Human endothelial cells prolong eosinophil survival. Regulation by cytokines and glucocorticoids. , 1989, Journal of immunology.
[5] P. Deuster,et al. Exercise and Circadian Rhythm-Induced Variations in Plasma Cortisol Differentially Regulate Interleukin-1β (IL-1β), IL-6, and Tumor Necrosis Factor-α (TNFα) Production in Humans: High Sensitivity of TNFα and Resistance of IL-6 , 1997 .
[6] T. Kral,et al. The immune-hypothalamic-pituitary-adrenal axis. , 1989, Endocrine reviews.
[7] P. Barnes,et al. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. , 1998, Clinical science.
[8] G. Chrousos,et al. Corticotropin releasing hormone related behavioral and neuroendocrine responses to stress in Lewis and Fischer rats , 1992, Brain Research.
[9] T. Insel,et al. The dexamethasone suppression test in patients with primary obsessive-compulsive disorder , 1982, Psychiatry Research.
[10] L. Phillips,et al. Glucocorticoid effects on somatomedins and somatomedin inhibitors. , 1985, The Journal of clinical endocrinology and metabolism.
[11] T. Bártfai,et al. Cytokine Regulation of Neuronal Survival , 1992, Journal of neurochemistry.
[12] G. Chrousos,et al. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.
[13] A. Waage,et al. Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts , 1990, European journal of immunology.
[14] P. Hindmarsh,et al. Direct effects of corticotrophin‐releasing hormone on stimulated growth hormone secretion , 1998, Clinical endocrinology.
[15] G. Chrousos,et al. Impairment of adrenocortical function associated with increased plasma tumor necrosis factor-alpha and interleukin-6 concentrations in African trypanosomiasis. , 1994, Neuroimmunomodulation.
[16] David Baltimore,et al. NF-κB: Ten Years After , 1996, Cell.
[17] P. Sawchenko,et al. Type 1 interleukin‐1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL‐1–induced cellular activation , 1995, The Journal of comparative neurology.
[18] S. Beck,et al. Chronic corticosterone treatment maintains synaptic activity of CA1 hippocampal pyramidal cells: Acute high corticosterone administration increases action potential number , 1995, Synapse.
[19] F. Goodwin,et al. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (2) , 1988, The New England journal of medicine.
[20] A. Grossman,et al. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. , 1995, The Journal of clinical endocrinology and metabolism.
[21] E. Sternberg. Emotions and disease: From balance of humors to balance of molecules , 1997, Nature Medicine.
[22] H. Yarwood,et al. Effect of glucocorticosteroids on microvascular permeability. , 1990, The American review of respiratory disease.
[23] S. Akira,et al. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF) , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[24] P. Landfield,et al. Modulation of brain aging correlates by long-term alterations of adrenal steroids and neurally-active peptides. , 1987, Progress in brain research.
[25] J. Cohen,et al. Programmed cell death in the immune system. , 1991, Advances in immunology.
[26] S. Lamberts,et al. Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. , 1984, The Journal of clinical endocrinology and metabolism.
[27] H. Imura,et al. Expression of adrenocorticotropin-releasing hormone precursor gene in placenta and other nonhypothalamic tissues in man. , 1988, Molecular endocrinology.
[28] D. Koutras. Disturbances of Menstruation in Thyroid Disease , 1997, Annals of the New York Academy of Sciences.
[29] E. Remmers,et al. Corticotropin-releasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis. , 1993, Journal of immunology.
[30] G. Chrousos,et al. Elevated cerebrospinal fluid levels of immunoreactive corticotropin-releasing hormone in anorexia nervosa: relation to state of nutrition, adrenal function, and intensity of depression. , 1987, The Journal of clinical endocrinology and metabolism.
[31] J V Castell,et al. Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.
[32] G. Chrousos,et al. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. , 1991, Science.
[33] P. J. Larsen,et al. Substance P Inhibits the Release of Anterior Pituitary Adrenocorticotrophin via a Central Mechanism Involving Corticotrophin‐Releasing Factor‐Containing Neurons in the Hypothalamic Paraventricular Nucleus , 1993, Journal of neuroendocrinology.
[34] G. Chrousos,et al. Basic and clinical studies with corticotropin-releasing hormone. Implications for a possible role in panic disorder. , 1988, The Psychiatric clinics of North America.
[35] W. Graninger,et al. Anterior pituitary function in patients with newly diagnosed rheumatoid arthritis. , 1996, British journal of rheumatology.
[36] Z. Werb. Biochemical actions of glucocorticoids on macrophages in culture. Specific inhibition of elastase, collagenase, and plasminogen activator secretion and effects on other metabolic functions , 1978, The Journal of experimental medicine.
[37] J. Calabrese,et al. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications. , 1986, The New England journal of medicine.
[38] M. Joëls,et al. Brain corticosteroid receptor balance in health and disease. , 1998, Endocrine reviews.
[39] K. Matsushima,et al. Dexamethasone inhibits the induction of monocyte chemotactic-activating factor production by IL-1 or tumor necrosis factor. , 1991, Journal of immunology.
[40] G. Chrousos,et al. Mechanisms of serotonin receptor agonist-induced activation of the hypothalamic-pituitary-adrenal axis in the rat. , 1990, Endocrinology.
[41] Y. Levo,et al. MAST-CELL DEGRANULATION IN CROHN'S DISEASE , 1978, The Lancet.
[42] U. Stenman,et al. Tumor necrosis factor as a potent inhibitor of adrenocorticotropin-induced cortisol production and steroidogenic P450 enzyme gene expression in cultured human fetal adrenal cells. , 1991, Endocrinology.
[43] S. Yen,et al. Expression of genes encoding corticotropin-releasing factor (CRF), type 1 CRF receptor, and CRF-binding protein and localization of the gene products in the human ovary. , 1997, The Journal of clinical endocrinology and metabolism.
[44] K. Umesono,et al. The nuclear receptor superfamily: The second decade , 1995, Cell.
[45] G. Chrousos,et al. Mechanisms of Glucocorticoid‐Resistant Asthma a , 1998, Annals of the New York Academy of Sciences.
[46] S. Akira,et al. Biological and clinical aspects of interleukin 6. , 1990, Immunology today.
[47] G. Chrousos,et al. Interactions between the Hypothalamic-Pituitary-Adrenal Axis and the Female Reproductive System: Clinical Implications , 1998, Annals of Internal Medicine.
[48] E. Unanue,et al. Corticosteroids inhibit murine macrophage Ia expression and interleukin 1 production. , 1982, Journal of immunology.
[49] G. Koob,et al. Corticotropin releasing factor produces behavioural activation in rats , 1982, Nature.
[50] R. Schleimer,et al. Inhibition of basophil histamine release by anti-inflammatory steroids , 1981, Nature.
[51] A. Herz,et al. A two-step mechanism by which corticotropin-releasing hormone releases hypothalamic beta-endorphin: the role of vasopressin and G-proteins. , 1989, Endocrinology.
[52] Lars Bäckman,et al. INTERLEUKIN-2-RECEPTOR BLOCKADE WITH DACLIZUMAB TO PREVENT ACUTE REJECTION IN RENAL TRANSPLANTATION , 1998 .
[53] L. de wit,et al. Glucocorticoid up-regulation of high-affinity interleukin 6 receptors on human epithelial cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[54] R. Schleimer,et al. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. , 1991, Journal of immunology.
[55] G. Chrousos,et al. In vitro and in vivo effects of the triazolobenzodiazepine alprazolam on hypothalamic-pituitary-adrenal function: pharmacological and clinical implications. , 1990, The Journal of clinical endocrinology and metabolism.
[56] R. Dluhy. The growing spectrum of HIV-related endocrine abnormalities. , 1990, The Journal of clinical endocrinology and metabolism.
[57] C. Qualls,et al. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans. , 1996, The Journal of clinical endocrinology and metabolism.
[58] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[59] H. Hechtman,et al. Endothelial-secreted arachidonic acid metabolites modulate polymorphonuclear leukocyte chemotaxis and diapedesis in vitro , 1988 .
[60] T. Kakigi,et al. Elevated urinary free cortisol in patients with dementia , 1991, Neurobiology of Aging.
[61] R. Flower,et al. The role of lipocortin in corticosteroid actions. , 1990, The American review of respiratory disease.
[62] B. Burguera,et al. Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man. , 1990, The Journal of clinical endocrinology and metabolism.
[63] S. Wessely,et al. Low-dose hydrocortisone in chronic fatigue syndrome: a randomised crossover trial , 1999, The Lancet.
[64] G. Chrousos,et al. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. , 1993, The Journal of clinical endocrinology and metabolism.
[65] D. Gladman,et al. Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis. , 1990, The Journal of rheumatology.
[66] G. Chrousos,et al. A corticotropin-releasing hormone type I receptor antagonist delays parturition in sheep. , 1998, Endocrinology.
[67] K. Bacon,et al. Potent and selective inhibition of in vitro lymphocyte migration by cyclosporine and dexamethasone. , 1990, Immunopharmacology and immunotoxicology.
[68] P. Rothwell,et al. Cortisol response to corticotropin and survival in septic shock , 1991, The Lancet.
[69] S. Lamberts,et al. Cortisol receptor resistance: the variability of its clinical presentation and response to treatment. , 1992, The Journal of clinical endocrinology and metabolism.
[70] G. Chrousos,et al. Abnormal neuroendocrine immune communications in patients with rheumatoid arthritis , 1992, European journal of clinical investigation.
[71] S. Lamberts,et al. Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. , 1995, The Journal of clinical endocrinology and metabolism.
[72] A. Baldwin,et al. THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .
[73] M. Karin,et al. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.
[74] G. Chrousos,et al. Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. , 1996, Endocrine reviews.
[75] M. Moroni,et al. Cortisol resistance in acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.
[76] G. Chrousos,et al. The Stress Response and the Regulation of Inflammatory Disease , 1992, Annals of Internal Medicine.
[77] D. Papanicolaou,et al. The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.
[78] M. Demitrack,et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. , 1991, The Journal of clinical endocrinology and metabolism.
[79] J. Born,et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. , 1998, The Journal of clinical endocrinology and metabolism.
[80] S. Szefler,et al. Steroid-resistant asthma. Cellular mechanisms contributing to inadequate response to glucocorticoid therapy. , 1994, The Journal of clinical investigation.
[81] R. Ekman,et al. Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes , 1993, Journal of Neuroimmunology.
[82] A. Dvorak,et al. MAST-CELL DEGRANULATION IN CROHN'S DISEASE , 1978, The Lancet.
[83] M. Atkins,et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects [see comments] , 1990 .
[84] G. Chrousos,et al. Increased plasma concentrations, hypothalamic content, and in vitro release of arginine vasopressin in inflammatory disease-prone, hypothalamic corticotropin-releasing hormone-deficient Lewis rats. , 1992, Endocrinology.
[85] S. Kasper,et al. Abnormal pituitary-adrenal responses to corticotropin-releasing hormone in patients with seasonal affective disorder: clinical and pathophysiological implications. , 1991, The Journal of clinical endocrinology and metabolism.
[86] A. Baldwin,et al. The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.
[87] M. Merino,et al. Presence of immunoreactive corticotropin releasing hormone in thyroid lesions. , 1994, The American journal of pathology.
[88] G. Chrousos,et al. Bone mineral density in women with depression. , 1996, The New England journal of medicine.
[89] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[90] A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. , 1998, The Journal of clinical endocrinology and metabolism.